A Less Costly Regimen of Alglucerase to Treat Gaucher's Disease
Open Access
- 3 December 1992
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 327 (23) , 1632-1636
- https://doi.org/10.1056/nejm199212033272304
Abstract
Alglucerase (Ceredase) provides effective enzyme-replacement treatment for patients with Gaucher's disease, but at the usually recommended dose of 60 U per kilogram of body weight every two weeks (130 U per kilogram per month), it costs $382,200 per year for a 70-kg patient. Theoretical considerations suggest that more frequent administration would be more efficient.Keywords
This publication has 14 references indexed in Scilit:
- Gaucher DiseaseMedicine, 1992
- Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher diseaseThe Journal of Pediatrics, 1992
- Prevention of Endometrial Hyperplasia in Postmenopausal Women with Intrauterine ProgesteroneNew England Journal of Medicine, 1991
- Enzyme-Replacement Therapy for Gaucher's DiseaseNew England Journal of Medicine, 1991
- Norrbottnian Type of Gaucher Disease – Clinical, Biochemical and Molecular Biology Aspects: Successful Treatment with Bone Marrow TransplantationDevelopmental Neuroscience, 1991
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991
- BENEFICIAL EFFECT OF PRE-TRANSPLANT SPLENECTOMY ON DISPLACEMENT BONE MARROW TRANSPLANTATION FOR GAUCHER'S SYNDROMEThe Lancet, 1987
- Bone-Marrow Transplantation in Severe Gaucher's DiseaseNew England Journal of Medicine, 1984
- Accurate Measurement of Liver, Kidney, and Spleen Volume and Mass by Computerized Axial TomographyAnnals of Internal Medicine, 1979
- DETECTION OF THE DEFECT OF GAUCHER'S DISEASE AND ITS CARRIER STATE IN PERIPHERAL-BLOOD LEUCOCYTESThe Lancet, 1970